Stryker Corp (NYSE: SYK) flaunted slowness of -1.18% at $358.67, as the Stock market unbolted on Thursday, before settling in for the price of $362.94 at the close. Taking a more long-term approach, SYK posted a 52-week range of $329.16-$406.19.
In the past 5-years timespan, the Healthcare sector firm’s annual sales growth was 7.20%. Meanwhile, its Annual Earning per share during the time was 7.20%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 11.19%. This publicly-traded company’s shares outstanding now amounts to $382.40 million, simultaneously with a float of $358.82 million. The organization now has a market capitalization sitting at $137.16 billion.
Stryker Corp (SYK) Ownership Facts and Figures
Sometimes it is also beneficial to study the sentiment of large-scale investors towards the stock of the Stryker Corp industry. Stryker Corp’s current insider ownership accounts for 6.17%, in contrast to 81.05% institutional ownership. According to the most recent insider trade that took place on Nov 20 ’25, this organization’s VP, Chief Financial Officer sold 165 shares at the rate of 365.88, making the entire transaction reach 60,370 in total value, affecting insider ownership by 6,694.
Stryker Corp (SYK) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of 3.06 per share during the current fiscal year.
Stryker Corp’s EPS increase for this current 12-month fiscal period is 11.19% and is forecasted to reach 14.97 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 11.18% through the next 5 years, which can be compared against the 7.20% growth it accomplished over the previous five years trading on the market.
Stryker Corp (NYSE: SYK) Trading Performance Indicators
Let’s observe the current performance indicators for Stryker Corp (SYK). It’s Quick Ratio in the last reported quarter now stands at 1.13. Alongside those numbers, its PE Ratio stands at $47.10, and its Beta score is 0.88. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 5.63. Similarly, its price to free cash flow for trailing twelve months is now 33.68.
In the same vein, SYK’s Diluted EPS (Earnings per Share) trailing twelve months is recorded 7.62, a figure that is expected to reach 4.39 in the next quarter, and analysts are predicting that it will be 14.97 at the market close of one year from today.
